quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·45d
PRRelease
Pulse Biosciences Inc logo

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

PLSE· Pulse Biosciences Inc
Health Care
Original source

Companies

  • PLSE
    Pulse Biosciences Inc
    Health Care

Recent analyst ratings

  • Jan 30UpdateMizuho$25.00
  • Jul 7UpdateOppenheimer$22.00
  • Feb 10UpdateHC Wainwright & Co.$20.00
  • Nov 16UpdateHC Wainwright & Co.$43.00
  • Jul 27UpdateStephens & Co.$28.00

Related

  • PR3d
    Pulse Biosciences' nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
  • PR6d
    Pulse Biosciences to Host Analyst Event on April 25, 2026
  • SEC7d
    Pulse Biosciences Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC14d
    Pulse Biosciences Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR14d
    Pulse Biosciences Strengthens Executive Leadership Team
  • SEC16d
    Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR16d
    Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
  • INSIDER20d
    SEC Form 4 filed by Uecker Darrin
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022